Heat shock protein expression in target cells infected with low levels of replication-competent virus contributes to the immunogenicity of adenoviral vectors

Human Gene Therapy

Volumn 10, Issue 9, 1999, Pages 1431-1442

  Melcher, Alan ^a,b   Murphy, Stephen ^a,b   Vile, Richard ^a,b  

^a MAYO CLINIC   (United States)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; GENE TRANSFER; IMMUNOGENICITY; IMMUNOMODULATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INDUCTION; TRANSGENE; VIRUS INFECTION; VIRUS INHIBITION; VIRUS REPLICATION;

ADENOVIRUSES, HUMAN; ANIMALS; GENE EXPRESSION; GENETIC VECTORS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PLASMIDS; RNA, MESSENGER; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALIA;

EID: 0033542468     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950017770     Document Type: Article

References (47)

1. AIELLO, L., GUILFOYLE, R., HUEBNER, K., and WEINMANN, R. (1979). Adenovirus 5 DNA sequences present and RNA sequences transcribed in transformed human embryo kidney cells (HEK-Ad-5 or 293). Virology 94, 460-469.
2. ALVAREZ, R. D., and CURIEL, D. T. (1997). A phase I study of recombinant adenovirus vector-mediated intraperitoneal delivery of herpes simplex virus thymidine kinase (HSV-TK) gene and intravenous ganciclovir for previously treated ovarian and extraovarian cancer patients. Hum. Gene Ther. 8, 597-613.
3. ARMENTANO, D., ZABNER, J., SACKS, C., SOOKDEO, C. C., SMITH, M. P., ST. GEORGE, J. A., WADSWORTH, S. C., SMITH, A. E., and GREGORY, R. J. (1997). Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. J. Virol. 71, 2408-2416.
4. BETT, A. J., HADDARA, W., PREVEC, L., and GRAHAM, F. L. (1994). An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc. Natl. Acad. Sci. U.S.A. 91, 8802-8806.
5. BISCHOFF, J., KIRN, D. H., WILLIAMS, A., HEISE, C., HORN, S., MUNA, M., NG, L., NYE, J., SAMPSON-JOHANNES, A., FATTAEY, A., and MCCORMICK, F. (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373-376.
6. CHEN, P. W., WANG, M., BRONTE, V., ZHAI, Y., ROSENBERG, S., and RESTIFO, N. P. (1996). Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J. Immunol. 156, 224-231.
7. CHINNDURAI, G., CHINNDURAI, S., and BRUSSA, J. (1979). Physical mapping of a large plaque mutation of adenovirus type 2. J. Virol. 32, 623-628.
8. CROUZET, J., NAUDIN, L., ORSINI, C., VIGNE, E., FERRERO, L., LEROUX, A., BENOIT, P., LATTA, M., TORRENT, C., BRANELLEC, D., DENEFLE, P., MAYAUX, J. F., PERRICAUDET, M., and YEH, P. (1997). Recombinational construction in Escherichia coli of infectious adenoviral genomes. Proc. Natl. Acad. Sci. U.S.A. 94, 1414-1419.
9. CRYSTAL, R. G. (1995). Transfer of genes to humans: Early lessons and obstacles to success. Science 270, 404-410.
10. ENGELHARDT, J. F., YE, X., DORANZ, B., and WILSON, J. M. (1994). Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. U.S.A. 91, 6196-6200.
11. FRISCH, S. M., and DOLTER, K. E. (1995). Adenovirus E1A-mediated tumour suppression by a c-erb-B-2/neu-independent mechanism. Cancer Res. 55, 5551-5555.
12. GRAHAM, F. L., SMILEY, J., RUSSELL, W. C., and NAIRN, R. (1977). Characterisation of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59-72.
13. HUANG, A. Y. C., GOLUMBEK, P., AHMADZADEH, M., JAFFEE, E., PARDOLL, D., and LEVITSKY, H. (1994). Role of bone marrow derived cells in presenting MHC class I-restricted tumor antigens. Science 264, 961-965.
14. ILAN, Y., PRAKASH, D., DAVIDSON, A., JONA, V., DROGUETT, G., HORWITZ, M. S., CHOWDHURY, N. R., and CHOWDHURY, J. R. (1977). Oral tolerization to adenoviral antigens permits long term gene expression using recombinant adenoviral vectors. J. Clin. Invest. 99, 1098-1106.
15. KETNER, G., SPENCER, F., TUGENDREICH, S., CONNELLY, C., and HIETER, P. (1994). Efficient manipulation of the human adenovirus genome as an infectious yeast artificial chromosome clone. Proc. Natl. Acad. Sci. U.S.A. 91, 6186-6190.
16. KOCHANEK, S., CLEMENS, P. R., MITANIS, K., CHEN, H.-H., CHAN, S., and CASKEY, C. T. (1996). A new adenoviral vector: Replacement of all viral coding sequences with 28kb of DNA independently expressing both full-length dystrophin and β-galactosidase. Proc. Natl. Acad. Sci. U.S.A. 93, 5731-5736.
17. KOZARSKY, K. F., and WILSON, J. M. (1993). Gene therapy: Adenovirus vectors. Curr. Opin. Genet. Dev. 3, 499-503.
18. LIEBER, A., HE, C. Y., KIRILLOVA, I., and KAY, M. A. (1996). Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J. Virol. 70, 8944-8960.
19. LOCHMULLER, H. J., JANI, A., HUARD, J., PRESCOTT, S., SIMONEAU, M., MASSIE, B., KARPATI, G., and ACSADI, G. (1994). Emergence of early region-1 containing replication competent adenovirus in stocks of replication defective adenovirus recombinants during multiple passages in 293 cells. Hum. Gene Ther. 5, 1485-1491.
20. LUKACS, K. V., NAKAKES, A., ATKINS, C. J., LOWRIE, D. B., and COLSTON, M. J. (1997). In vivo gene therapy of malignant tumours with heat shock protein-65 gene. Gene Ther. 4, 346-350.
21. MASTRANGELI, A., HARVEY, B.-G., YAO, J., WOLFF, G., KOVESDI, L. CRYSTAL, R. G., and FALCK-PEDERSEN, E. (1996). "Sero-switch" adenovirus mediated in vivo gene transfer: Circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum. Gene Ther. 7, 79-88.
22. MCGRORY, W. J., BAUTISTA, D. S., and GRAHAM, F. L. (1988). A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology 163, 614-617.
23. MELCHER, A. A., TODRYK, S., HARDWICK, N., FORD, M., JACOBSON, M., and VILE, R. G. (1998). Tumor immunogenicity is determined by the mechanism of cell death via induction of heat protein expression. Nature Med. 4, 581-587.
24. MIYAKE, S., MAKIMURA, M., KANEGAE, Y., HARADA, S., SATO, Y., TAKAMORI, K., TOKUDA, C., and SAITO, I. (1996). Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. Proc. Natl. Acad. Sci. U.S.A. 93, 1320-1324.
25. PAILLARD, F. (1998). Circumventing adenovirus immune response to achieve long-term correction of genetic diseases. Hum. Gene Ther. 9, 454-456.
26. PARKS, R. J., CHEN, L., ANTON, M., SANKAR, U., RUDNICKI, A., and GRAHAM, F. L. (1996) A helper-dependent adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. U.S.A. 93, 13565-13570.
27. PHILIPS, B., ABRAVAYA, K., and MORIMOTO, R. I. (1991). Analysis of the specificity and mechanism of transcriptional activation of the human hsp70 gene during infection by DNA viruses. J. Virol. 65, 5680-5692.
28. PLAUTZ, G. E., YANG, Z., WU, B., GAO, X., HUANG, L., and NABEL, G. J. (1993). Immunotherapy of malignancy by in vivo gene transfer into tumours. Proc. Natl. Acad. Sci. U.S.A. 90, 4645-4649.
29. RUSSELL, S. J., ECCLES, S. A., FLEMMING, C. L., JOHNSON, C. A., and COLLINS, M. K. L. (1991). Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of an IL-2 cDNA. Int. J. Cancer 47, 244-251.
30. SCHIEDNER, G., MORRAL, N., PARKS, R. J., WU, Y., KOOPMANS, S. C., LANGSTON, C., GRAHAM, F. L., BEAUDET, A. L., and KOCHANEK, S. (1998). Genomic DNA transfer with a high capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nature Genet. 18, 180-183.
31. SONG, W., KONG, H.-L., TRAKTMAN, P., and CRYSTAL, R. G. (1997). Cytotoxic T lymphocyte responses to proteins encoded by heterologous transgenes transferred in vivo by adenoviral vectors. Hum. Gene Ther. 8, 1207-1217.
32. SRIVASTAVA, P. K., MENORET, A., BASU, S., BINDER, R. J., and MCQUADE, K. L. (1998). Heat shock proteins come of age: Primitive functions acquire new roles in an adaptive world. Immunity 8, 657-665.
33. SUTO, R., and SRIVASTAVA, P. K. (1995). A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 269, 1585-1588.
34. TAMURA, Y., PENG, P., LIU, K., DAOU, M., and SRIVASTAVA, P. K. (1997). Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278, 117-120.
35. VILE, R. G., and HART, I. R. (1993). Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res. 53, 3860-3864.
36. VILE, R., MILLER, N., CHERNAJOVSKY, Y., and HART, I. (1994a). A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL2 genes. Gene Ther. 1, 307-316.
37. VILE, R. G., NELSON, J. A., CASTLEDEN, S., CHONG, H., and HART, I. R. (1994b). Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. 54, 6228-6234.
38. WAINBERG, Z., OLIVEIRA, M., LERNER, S., TAO, Y., and BRENNER, B. G. (1997). Modulation of stress protein (hsp27 and hsp70) expression in CD4+ lymphocytic cells following acute infection with human immunodeficiency virus type-1. Virology 233, 364-373.
39. WANG, Q., GREENBURG, G., BUNCH, D., FARSON, D., and FINER, M. H. (1997). Persistent transgene expression in mouse liver following in vivo gene transfer with an E1/E4 adenovirus vector. Gene Ther. 4, 393-400.
40. WEI, Y.-Q., ZHAO, X., KARIYA, Y., FUKATA, H., TESHIGAWA, K., and UCHIDA, A. (1996). Induction of autologous tumor killing by heat treatment of fresh human tumor cells: Involvement of γδ T cells and heat shock protein 70. Cancer Res. 56, 1104-1110.
41. WU, B. J., HURST, H. C., JONES, N. C., and MORIMOTO, R. I. (1986). The E1A 13S product of adenovirus 5 activates transcription of the cellular human HSP70 gene. Mol. Cell. Biol. 6, 2994-2999.
42. XIANG, Z. Q., YANG, Y., WILSON, J. M., and ERTL, H. C. (1996). A replication defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology 219, 220-227.
43. YANG, Y., NUNES, F. A., BERENCSI, K., FURTH, E. E., GONCZOL, E., and WILSON, J. M. (1994). Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. U.S.A. 91, 4407-4411.
44. YANG, Y., LI, Q., ERTL, C. J. H., and WILSON, J. (1995a). Cellular and humoural immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69, 2004-2015.
45. YANG, Y., TRINCHIERI, G., and WILSON, J. M. (1995b). Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nature Med. 1, 890-893.
46. ZHANG, W.-W., KOCH, P., and ROTH, J. A. (1995). Detection of wild-type contamination in a recombinant adenoviral preparation by PCR. BioTechniques 18, 444-447.
47. ZHOU, H., O'NEAL, W., MORRAL, N., and BEAUDET, A. L. (1996). Development of a complementing cell line and a system for construction of adenoviral vectors. J. Virol. 70, 7030-7038.